Literature DB >> 10147373

Considerations for inter-hospital extracorporeal cardiopulmonary support resuscitation and transport.

J B Bennett1, J G Hill, W B Long.   

Abstract

The availability of commercial, pre-packaged extracorporeal cardiopulmonary support (ECPS) circuits, which are simplified for rapid set-up and priming, has made the intra-hospital resuscitation of moribund patients routine. The successful utilization of this technology in the emergent setting requires planning and the coordination of personnel familiar with the technology. Many issues must be addressed when a patient requiring life-sustaining support utilizing this technology at an outlying hospital, must be transported while on ECPS. After reducing the size and weight of the ECPS cart and obtaining Federal Aviation Administration approval for use during aeromedical transport, the Emanuel Hospital Mobile Surgical Transport Team (MSTT) was able to extend the use of emergency cardiopulmonary bypass to outlying medical facilities. The patients selected for transport, using ECPS, are a group of patients with a potentially survivable pathology unlikely to survive inter-hospital transport without such measures. This report describes our experience with inter-hospital transport of patients on ECPS with special emphasis on transport considerations.

Entities:  

Mesh:

Year:  1994        PMID: 10147373

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  2 in total

1.  Novel multi-functional life support system.

Authors:  David P Webb; Darren Jackson; Ehab S Kasasbeh; Jayant Bagai; David X Zhao
Journal:  J Extra Corpor Technol       Date:  2010-09

2.  Extracorporeal circulatory systems in the interhospital transfer of critically ill patients: experience of a single institution.

Authors:  Assad Haneya; Alois Philipp; Maik Foltan; Thomas Mueller; Daniele Camboni; Leopold Rupprecht; Thomas Puehler; Stephan Hirt; Michael Hilker; Reinhard Kobuch; Christof Schmid; Matthias Arlt
Journal:  Ann Saudi Med       Date:  2009 Mar-Apr       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.